he 2026 World Conference on Lung Cancer, held on September 12–15, featured a record 19 oral presentations and 45 mini oral presentations by Chinese innovative drugs, while Phase III overall survival results met their endpoints for HANSOH PHARMA's B7-H3-targeted ADC risvutatug rezetecan and for AKESO's HARMONi-2, lifting China's pharmaceutical sector. The Chinaamc Hang Seng Hong Kong Biotech Index ETF (3069.HK) posted outstanding constituent performance, with GENSCRIPT BIO surging 15% intraday on September 17 and driving the ETF up nearly 2% against the market trend.
on 17 September 2026, PCB-themed shares traded with volatility and pulled back, while DELTON (01989.HK) weakened. As of 14:10, the company quoted HKD 117.000, down 4.41%.
on 17 September 2026, AI chip stocks traded with volatility and pulled back, with ASMPT (00522.HK) weakening. As of 13:45, the company quoted HKD 158.000, down 2.05%.
on 17 September 2026, humanoid robot stocks strengthened while XIAOMI-W (01810.HK) weakened. As of 13:24, the company quoted HKD 25.900, down 1.07%.
On 17 September 2026, Direct Drive Tech Limited passed the listing hearing for the Main Board of HKEX, with CITIC Securities as sole sponsor; the Company is a robotics technology company with direct drive technology as its core capability, primarily engaging in the sales of robotic actuator modules, and ranked first in the PRC consumer robotic direct drive actuator module industry with a 61.1% market share and second in the PRC dual-wheel-legged robot industry with an 18.6% market share by 2025 revenue.
On 16 September 2026, Red Avenue New Materials Group Co., Ltd. (603650.SH) updated its Post Hearing Information Pack and passed the listing hearing for the Main Board of HKEX, with Haitong International as sole sponsor; the Company is a comprehensive new materials provider and ranked first in sales revenue in both the global and PRC phenolic resins rubber additives for tyres markets in FY2025, with market shares of 41.4% and 45.9%.
CSOP Solactive Asia AI Bottleneck Index ETF (Stock Code: 3499.HK, Short Name: CSOP AI Bottleneck) was officially listed on the Main Board of the Hong Kong Stock Exchange today (17 September 2026), offering investors a convenient vehicle to directly access the AI computing infrastructure boom.
On 16 September 2026, ZIJIN MINING (02899.HK) announced that its wholly-owned subsidiary Zijin Xiamen Equity entered into a partnership agreement on 15 September to subscribe RMB 1,000 million for a 20.4081% interest in the Shidai Shenyuan Fund, a co-investment constituting a connected transaction.
On 17 September 2026, China Changbaishan International Holdings Limited (00989.HK) and the offeror Ground Group (Hong Kong) Co., Limited jointly published a composite document for an unconditional mandatory cash offer to acquire all the issued shares at HK$ 0.15 in cash per share, with the latest time for acceptance at 4:00 p.m. on 8 October 2026.
On 16 September 2026, Quantgroup Holding Limited (02685.HK) entered into a placing agreement to place up to 48,529,412 shares at HK$ 3.40 per share, a discount of approximately 15.32% to the closing price of HK$ 4.015 on the same date, with net proceeds expected to be approximately HK$ 162.6 million.
On 16 September 2026, Fu Shou Yuan International Group Limited (01448.HK) announced the findings of an independent forensic investigation, in which the forensic accountant identified 69 suspicious transactions involving RMB 23,412,645, reduced to 64 transactions and RMB 22,767,433 after eliminating double counting; the Company's shares remain suspended from trading.
On 16 September 2026, AEON Stores (Hong Kong) Co., Limited (00984.HK) announced that its wholly-owned subsidiary AEON South China entered into a third supplemental agreement with the landlord in respect of the renewal agreement to reduce the unit rental price of the premises, cutting the total rent payable for the remaining lease term (excluding taxes) from approximately RMB 495 million to approximately RMB 359 million.
On 16 September 2026, Fujian Haixi Pharmaceuticals Co., Ltd. (02637.HK) announced that the 24-week treatment data observation of the China Phase I clinical study of its self-developed candidate drug molecule HX9428 for the treatment of neovascular age-related macular degeneration (nAMD) has been completed, while the Phase II dose expansion study is ongoing with interim data obtained; among the 13 patients who completed 24 weeks of treatment in Phase I, BCVA improved by an average of 5.2 letters from baseline and CST decreased by an average of 73.3 μm.
On 16 September 2026, China Merchants Land Limited (00978.HK) announced that its indirect non-wholly-owned subsidiary Foshan China Merchants Baohua Real Estate Co., Ltd. entered into an agreement for the resumption of state-owned land use rights in respect of a land plot in Nanhai District, Foshan City with the Land Reserve Centre of Nanhai District and the Guicheng Subdistrict Office, for aggregate cash compensation of RMB 569,067,951.00.
On 16 September 2026, CSPC PHARMA (01093.HK) announced that the Phase II clinical trial (SYH2069-003) of SYH2069 injection, developed by the Group, for the treatment of adult type 2 diabetes has formally commenced at the first study site in China.
On 16 September 2026, PATEO (02889.HK) announced that Mr. Liang Chen, vice president of the Company's procurement centre, acquired an aggregate of 27,740 H shares of the Company on the open market using his own funds on 16 September 2026, representing approximately 0.017% of the total issued shares, for an aggregate consideration of approximately RMB 2 million at an average price of approximately HKD 84.28 per share.
